Swedish Orphan Biovitrum Management
Management criteria checks 3/4
Swedish Orphan Biovitrum's CEO is Guido Oelkers, appointed in May 2017, has a tenure of 6.92 years. total yearly compensation is SEK48.88M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth SEK104.77M. The average tenure of the management team and the board of directors is 5.3 years and 3.4 years respectively.
Key information
Guido Oelkers
Chief executive officer
kr48.9m
Total compensation
| CEO salary percentage | 25.1% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 27
Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Apr 24Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 06Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Mar 05Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 15Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors
Jan 17Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Nov 24Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jul 07Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Apr 02Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?
Jan 11These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well
Dec 27Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Sep 28Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jun 26Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet
Mar 28Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?
Nov 17Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Sep 19An Intrinsic Calculation For Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Suggests It's 50% Undervalued
Aug 12Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has A Meaningful Debt Burden
Jun 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | kr2b |
| Dec 31 2023 | kr49m | kr12m | kr2b |
| Sep 30 2023 | n/a | n/a | kr3b |
| Jun 30 2023 | n/a | n/a | kr3b |
| Mar 31 2023 | n/a | n/a | kr3b |
| Dec 31 2022 | kr47m | kr11m | kr3b |
| Sep 30 2022 | n/a | n/a | kr2b |
| Jun 30 2022 | n/a | n/a | kr3b |
| Mar 31 2022 | n/a | n/a | kr3b |
| Dec 31 2021 | kr42m | kr10m | kr3b |
| Sep 30 2021 | n/a | n/a | kr3b |
| Jun 30 2021 | n/a | n/a | kr3b |
| Mar 31 2021 | n/a | n/a | kr3b |
| Dec 31 2020 | kr33m | kr10m | kr3b |
| Sep 30 2020 | n/a | n/a | kr3b |
| Jun 30 2020 | n/a | n/a | kr3b |
| Mar 31 2020 | n/a | n/a | kr4b |
| Dec 31 2019 | kr33m | kr10m | kr3b |
| Sep 30 2019 | n/a | n/a | kr3b |
| Jun 30 2019 | n/a | n/a | kr3b |
| Mar 31 2019 | n/a | n/a | kr3b |
| Dec 31 2018 | kr26m | kr9m | kr2b |
| Sep 30 2018 | n/a | n/a | kr2b |
| Jun 30 2018 | n/a | n/a | kr2b |
| Mar 31 2018 | n/a | n/a | kr1b |
| Dec 31 2017 | kr16m | kr5m | kr1b |
Compensation vs Market: Guido's total compensation ($USD4.47M) is above average for companies of similar size in the Swedish market ($USD2.32M).
Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.
CEO
Guido Oelkers (58 yo)
6.9yrs
Tenure
kr48,883,000
Compensation
Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 6.9yrs | kr48.88m | 0.11% SEK 104.8m | |
| Chief Financial Officer | 5.8yrs | no data | 0.015% SEK 13.9m | |
| General Counsel & Head of Legal Affairs | 5.3yrs | no data | 0.0079% SEK 7.5m | |
| Head of Strategy & Corporate Development | 2.3yrs | no data | 0.0058% SEK 5.5m | |
| Head of Human Resources | 1.3yrs | no data | no data | |
| Senior Scientific & Medical Advisor | 7.3yrs | no data | 0.0047% SEK 4.5m | |
| Head of International | 6.5yrs | no data | 0.010% SEK 9.8m | |
| Head of Europe | 5.3yrs | no data | 0.0078% SEK 7.5m | |
| Head of North America | 3.3yrs | no data | no data | |
| Head of Strategic Transformation Operations | no data | no data | 0.0018% SEK 1.8m | |
| Head of Technical Operations | 2.1yrs | no data | 0.0030% SEK 2.9m | |
| Senior VP | 1.3yrs | no data | no data |
5.3yrs
Average Tenure
55.5yo
Average Age
Experienced Management: SOBI's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Scientific Advisory Board | 23.3yrs | kr158.00k | no data | |
| Director | 13yrs | kr828.00k | 0.0059% SEK 5.6m | |
| Director | less than a year | kr463.00k | 0.00088% SEK 840.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 9.9yrs | kr770.00k | 0.0010% SEK 955.0k | |
| Independent Director | 3.9yrs | kr827.00k | 0.0019% SEK 1.8m | |
| Director | 2.9yrs | kr673.00k | 0.00015% SEK 143.3k | |
| Employee Representative Director | 1.3yrs | no data | no data | |
| Independent Director | less than a year | kr433.00k | no data |
3.4yrs
Average Tenure
53.5yo
Average Age
Experienced Board: SOBI's board of directors are considered experienced (3.4 years average tenure).